Noile-Immune Biotech Inc. [4893.T]
TOKYO, May 18 (Pulse News Wire) – Noile-Immune Biotech Inc. (4893.T) announced today the termination of its partnership agreement with Adaptimmune Limited, which had been in place since August 2019.
The collaboration involved applying Noile-Immune's proprietary PRIME technology to Adaptimmune’s TCR-T cell therapy research and development. Both companies agreed to end the partnership based on a comprehensive evaluation of progress, capacity, and resource allocation. The decision to terminate the partnership does not reflect any concerns regarding the safety or efficacy of the PRIME technology but rather stems from mutual strategic considerations.
Noile-Immune remains focused on developing its lead pipeline candidate, NIB103, and will continue to demonstrate the utility of PRIME through ongoing internal efforts. The company expects the impact on its fiscal year ending December 2026 to be minor. However, Noile-Immune stated it would promptly disclose any significant developments related to this matter.
🟢 Confidence: High AI-translated content.